Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation

Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. © 2016 Elsevier B.V.Embargo Period 12 month

CIK細胞と培養肥満細胞を併用し人為的抗腫瘍効果を増強させた造血幹細胞移植の開発

造血幹細胞移植は血液悪性腫瘍の治療法として普及しているが、免疫の攻撃から腫瘍細胞が逃避することや副作用である移植片対宿主病の克服といった解決すべき問題点を抱えている。我々はマウスの骨髄移植モデルを用いて抗腫瘍効果を増強し、移植片対宿主病のリスクを軽減した移植法の開発を目指している。本研究では培養肥満細胞が同種免疫反応に対し抑制的に作用することを見出した。Hematopoietic stem cell transplantation has been used in the treatment for hematological malignancy. The escape of tumor cells from immune attack, and graft-versus-host disease are unsolved problems. The aim of our study is development of transplantation with enhanced anti-tumor effect and reduced risk of graft-versus host disease. In this study, we have found that cultured mast cells suppress the allo-immune response.研究課題/領域番号:17K10101, 研究期間(年度):2017-04-01 - 2020-03-31出典：「CIK細胞と培養肥満細胞を併用し人為的抗腫瘍効果を増強させた造血幹細胞移植の開発」研究成果報告書　課題番号17K10101（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-17K10101/17K10101seika/）を加工して作

Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol

Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand hematopoietic stem cell transplantation.Methods: Patients with high-risk neuroblastoma will be enrolled in this study. A totalof 8 patients will be registered. Patients will receive 666 MBq/kg of 131I-MIBG andafter safety evaluation will undergo high-dose chemotherapy and hematopoietic stemcell transplantation. Autologous and allogeneic stem cell sources will be accepted.After engraftment or 28 days after hematopoietic stem cell transplantation, the safetyand response will be evaluated.Conclusion: This is the first prospective study of 131I-MIBG with high-dosechemotherapy and hematopoietic stem cell transplantation in Japan. The results willbe the basis of a future nationwide clinical trial